Mirum Pharmaceuticals Reports Positive Phase 2b Results for Brelovitug in Chronic Hepatitis Delta Virus
MIRM has more than doubled off its 52-week low of $39.51.
Summary
Mirum Pharmaceuticals reported positive Phase 2b results for its investigational drug brelovitug in chronic hepatitis delta virus, meeting the primary endpoint with strong efficacy and a favorable safety profile.
Key Events · Product Development and Regulatory · MIRM
-
Brelovitug Meets Primary Endpoint in AZURE-1 Study
The Phase 2b portion of the AZURE-1 study for brelovitug, an investigational monoclonal antibody for chronic hepatitis delta virus (HDV), met its primary endpoint.
-
Demonstrates Robust Antiviral Activity
100% of patients in the 300 mg QW arm and 75% in the 900 mg Q4W arm achieved virologic response, compared to 0% in the delayed treatment arm. The primary composite endpoint was achieved in 45% and 35% of patients, respectively.
-
Well-Tolerated Safety Profile
Treatment with brelovitug was well tolerated across dose groups, with a favorable safety profile.
-
Clear Path to Market
Topline data from Phase 3 studies are expected in H2 2026, with potential BLA submission and commercial launch in the U.S. in 2027.
Analysis · MIRM · Life Sciences
Mirum Pharmaceuticals announced highly positive Phase 2b results for brelovitug in treating chronic hepatitis delta virus (HDV), a significant de-risking event for the program. The drug demonstrated robust antiviral activity, with 100% and 75% virologic response rates in the two dose arms, respectively, compared to 0% in the control group. The primary composite endpoint of virologic response and ALT normalization was also met with strong statistical significance. The favorable safety profile further supports its potential as a single-agent therapy. These results pave a clear path towards anticipated Phase 3 data in H2 2026 and a potential BLA submission and commercial launch in 2027, significantly enhancing the company's pipeline value and future revenue prospects.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIRM was trading at $92.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $39.51 to $109.28. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.